04 October 2015

Beximco Pharma launches generic version of revolutionary hepatitis C drug Harvoni

Beximco Pharma has recently launched the revolutionary hepatitis C drug under the brand name Lesovir C which is a combination of Sofosbuvir and Ledipasvir.

This has been the first generic version in the world and the main objective is to make this latest and highly expensive medicine affordable to our patients. Lesovir C is available at around $13 per tablet whereas the innovator brand Harvoni from Gilead Inc. costs around $1125 per tablet. The fixed dose combination ledipasvir-sofosbuvir (90 mg/400 mg) is FDA-approved for the treatment of chronic hepatitis C with a cure rate of about 95%.